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Abstract
Background: Diabetic foot infections (DFI) present a major morbidity, mortality and economic challenge for the
tertiary health sector. However, lack of high quality evidence for specific treatment regimens for patients with DFIs
may result in inconsistent management. This study aimed to identify DFI caseload proportion and patterns of clinical
practice of Infectious Diseases (ID) Physicians and Trainees within Australia and New Zealand.
Methods: A cross-sectional online survey of Australian and New Zealand ID Physicians and Trainees was undertaken, to
estimate the overall ID caseload devoted to patients with DFIs and assess clinicians’ management practices of patients
with DFIs.
Results: Approximately 28% (142/499) of ID Physicians and Trainees from Australia and New Zealand responded to
the survey. DFI made up 19.2% of all ID consultations. Involvement in multidisciplinary teams (MDT) was common as
77.5% (93/120) of those responding indicated their patients had access to an inpatient or outpatient MDT. Significant
heterogeneity of antimicrobial treatments was reported, with 82 unique treatment regimens used by 102 respondents
in one scenario and 76 unique treatment regimens used by 101 respondents in the second scenario. The duration of
therapy and the choice of antibiotics for microorganisms isolated from superficial swabs also varied widely.
Conclusions: Patients with DFIs represent a significant proportion of an ID clinician’s caseload. This should be reflected
in the ID training program. Large heterogeneity in practice between clinicians reflects a lack of evidence from
well-designed clinical trials for patients with DFI and highlights the need for management guidelines informed by
future trials.
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Background
The current regional and international epidemic of dia-
betes mellitus has led to increasing numbers of people
with diabetic foot infections (DFI) [1–4]. The 2015 Aus-
tralian National Diabetes Audit found that 3.4% of pa-
tients in diabetes centres had a current foot ulcer, a two-
fold increase since 2009 [5]. Diabetic foot ulcers become
infected in approximately 50% of cases [6], with amputa-
tion required in over 15% [7]. A recent meta-analysis re-
ported an estimated 3.4% of inpatients are affected by
DFI [8] with foot infections now resulting in more hos-
pitalisations than any other diabetes-related complica-
tion in Australia [9].
The creation of multidisciplinary teams (MDTs) and
best practice guidelines have improved care of patients
with ulcers and DFI [10] and have resulted in fewer
diabetes foot-related hospitalisations and major ampu-
tations in some Australian centres [11, 12]. Current
published management guidelines on DFI [13–15],
however, are limited by a relative lack of published clin-
ical trials comparing efficacy of various antimicrobial
regimens [16]. Furthermore, recommendations taking
into account geographic differences in the resistance
rates of organisms to antimicrobials are sparse [17, 18].
Therefore, DFIs are now considered a clinical trial
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priority area by the Australasian Society of Infectious
Diseases [19].
DiabEtic Foot Infections Australia New Zealand
(DEFIANZ) is an interdisciplinary DFI interest group
formed through the Australasian Society of Infectious
Diseases Clinical Research Network. This preliminary
study was undertaken to understand current clinical
management of DFI in Australia and New Zealand and
to identify areas of heterogeneity or clinical equipoise to
inform future clinical trials. We aimed to identify
current patterns in the clinical management of patients
with DFI by Adult Infectious Diseases (ID) Physicians
and Advanced Trainees in Australia and New Zealand
and to determine the relative caseload of patients with
DFI in this population.
Methods
This cross-sectional study of Australian and New Zea-
land ID clinicians was conducted using an online survey
(Survey Monkey, Palo Alto, CA, USA). Eligible partici-
pants of the survey were all Adult ID Physicians and
Trainees who were currently registered and practicing in
Australia or New Zealand. In 2015, there were 389 ID
Physicians recorded with the Australian Health Practi-
tioner Regulation Agency [20] and an estimated 60 Ad-
vanced Trainees. In New Zealand it is estimated there
were 41 ID Physicians and 9 Trainees [21].
The survey was developed by the members of
DEFIANZ and piloted by eight clinicians across
Australia and New Zealand for feedback on practicality
and content validity. The final items contained in the
survey were agreed by consensus by the 19 members of
DEFIANZ. Additional file 1 displays the final 26-item
survey covering sections on demographics, clinical ex-
perience and caseloads, involvement with MDT, clinical
practice compared to the Therapeutic Guidelines: Anti-
biotic [22], and two standardised clinical scenarios (see
also Table 1).
The Australian Therapeutic Guidelines: Antibiotic rec-
ommend empiric treatment of i) mild to moderate foot in-
fections in patients with diabetes and no evidence of
osteomyelitis or septic arthritis with amoxicillin-clavulanate
or cephalexin plus metronidazole, and ii) severe limb or
life threatening infection with piperacillin-tazobactam
or ticarcillin-clavulanate with addition of vancomycin
based on local epidemiology [22].
The primary outcome of interest was a comparative
assessment of clinical management patterns of patients
with DFI through two clinical scenarios. The secondary
outcomes were proportional caseload attributed to inpa-
tients and outpatients with DFI by ID clinicians and
assessment of clinician involvement in MDTs.
The link to the online survey was emailed to potential
participants via professional email forums with a follow-
up reminder. The survey was conducted during a 4 week
period in November and December 2015. The survey
was also advertised weekly through the Australasian So-
ciety of Infectious Diseases electronic newsletter during
the survey period. Survey responses with less than two
completed items were deemed ineligible.
Statistical analysis was undertaken using Stata, version
14 (Statacorp). Descriptive statistics were used to display
all variables; using proportions for categorical variables
and means (standard deviations) or medians (inter-quar-
tile ranges) for continuous variables with and without
normal distributions, respectively. Calculation of summary
statistics for antibiotic duration assumed the maximum
duration within each response category. Respondents that
answered ‘unsure’ were excluded from that question
unless otherwise specified. As not all survey participants
Table 1 Standardised clinical scenarios from survey
Scenario 1
Part A:
A highly functioning 63 year old lady with a history of hypertension
and poorly controlled type 2 diabetes mellitus is found to have a
deep heel ulcer which has been present for five weeks. She has had
no previous treatment. She is afebrile with normal heart rate and
blood pressure. Examination reveals a deep 2 × 3 cm ulcer with 3 cm
of surrounding cellulitis and purulent discharge consistent with
infection. The ulcer does not probe to bone. Peripheral pulses are
present and her foot has good capillary refill, but there is evidence of
peripheral neuropathy.
Her white blood cell count is normal, ESR is 55 and a plain X-ray
does not show osteomyelitis. A CT angiogram two months earlier
revealed good arterial blood flow to both legs. She has no allergies,
is a low anaesthetic risk and has normal renal function.
You decide to investigate for osteomyelitis. What technique would
you use (assuming all are available)?
Part B:
The imaging reveals no evidence of osteomyelitis, but evidence of
deep soft tissue infection. Surgical debridement is undertaken but
residual infection remains with non-debrided deep soft tissue
samples growing fully sensitive E. coli, fully sensitive P. aeruginosa
and methicillin sensitive S. aureus (MSSA) (penicillin-resistant). She is
not known to be colonised by MRSA and there is a low prevalence
of MRSA at your institution. Adherence is not thought likely to be
an issue. What antibiotic strategy would you choose?
Scenario 2
A highly functioning, independent 65 year old retired man with
poorly controlled type 2 diabetes mellitus but no previous
complications develops an ulcer overlying his 5th metatarsal head.
After six weeks without treatment he attends your hospital and is
found to have osteomyelitis of his 5th metatarsal head. He is afebrile
with an ESR of 75. There is evidence of peripheral neuropathy and
moderate peripheral arterial disease with an ankle brachial index of
0.5. A CT angiogram reveals distal small vessel disease that cannot be
corrected surgically or endovascularly. He has no allergies and has
normal renal function. He is not known to be colonised with MRSA
and there is a low prevalence of MRSA at your institution. He has
previously been adherent to oral medication and is thought to be
reliable with taking medication.
The patient is concerned amputation will impact on his golf and
refuses amputation. He undergoes debridement of the ulcer and
bone. Moderate growth of MSSA (penicillin resistant) is cultured
from non-debrided deep tissue and direct microscopy reveals Gram-
positive cocci. The surgeon says that there is some residual infected
bone and tissue but the bone appears healthy. What antibiotic
strategy would you choose?
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answered every question, the number of respondents an-
swering a question was used as the denominator for the
relevant results of that question. The Wilcoxon rank sum
test was used to compare non-parametric continuous vari-
ables. Treatment regimens were considered unique if
there was a difference in antibiotic duration or delivery
method (e.g. inpatient intravenous, outpatient intravenous
or oral).
Results
A total of 159 survey responses were received. Of those,
17 were deemed ineligible and excluded, leaving a re-
sponse rate of 28% (142/499) and a full completion rate
of 73% (103/142). Participant characteristics are detailed
in Table 2. Participants were from all Australian jurisdic-
tions and six of 16 New Zealand regions.
Caseload
Patients with DFI were estimated to represent 19.2%
(586/3053) of all patients seen by responding ID clini-
cians per week; with patients with DFI accounting for
21.0% (197/936) of consultations by Trainees and 18.4%
(389/2117) of consultations by consultant physicians.
Overall inpatient caseload was 18.3% (345/1885) and
outpatient caseload was 20.6% (241/1168) per week.
The most common setting for DFI consultations was
as inpatients in the public hospital system (97.5%; 117/
120), with 83.3% (100/120) of participants seeing DFI
consultations as outpatients in the public hospital sys-
tem and 19.2% of participants seeing DFI consultations
in the private system. Four participants (3.3%; 4/120)
could access telehealth services to also see patients. The
majority of participants had on-site podiatry (93.9%;
107/114), diabetes review services (99.2%; 118/119) and
vascular surgery services (88.3%; 106/120). Non-removable
offloading devices (90%; 81/90) and outpatient parenteral
antimicrobial therapy (99.2%; 120/121) were also com-
monly available.
Multidisciplinary diabetic foot teams
Public hospital MDT were reported as available for 77.5%
(93/120) of participants overall, with MDT for inpatients
reported available by 50.0% (59/118) of participants and
for outpatients by 59.3% (70/118) of participants. MDT
consultation was reported as usually weekly or more fre-
quently for inpatients and outpatients (65.5%; 38/58 and
65.6%; 42/64, respectively). Where MDT were available,
participants often reported direct involvement (78.4%; 58/
74) and attended most MDT sessions (72.7%; 40/55).
Clinical management
Most (76.7%; 79/103) participants indicated they would
treat mild to moderate DFI in accordance with Thera-
peutic Guidelines [22] > 60% of the time. The majority
(61.2%; 63/103) of participants would prescribe antibi-
otics to treat all organisms isolated from superficial
Table 2 Survey participant characteristics and diabetic foot infection-related caseload
Physicians Trainees
No. Responses (% unless
otherwise stated)
No. of respondents who
answered the question
No. Responses (% unless
otherwise stated)
No. of respondents who
answered the question
Total number 103 (70%) 103 39 (30%) 39
Location
Australia 77 (87%) 89 29 (94%) 31
Metropolitan (capital) 62 (81%) 77 21 (72%) 29
Urban (> 100,000) 13 (17%) 77 8 (28%) 29
Rural (< 100,000) 2 (3%) 77
New Zealand 14 (13%) 89 2 (6%) 31
Metropolitan 4 (29%) 14 1 (50%) 2
Urban 9 (64%) 14 1 (50%) 2
Rural 1 (7%) 14
Years of experience (median, IQR) 7 [3, 15] 103
Year of training (median, IQR) 2 [1,3] 39
No of ID consultations per week
Inpatient (median, IQR) 11 [6, 16] 89 21 [16.5, 30] 31
Outpatient (median, IQR) 9 [6, 16] 89 9 [6, 11] 31
No of DFI consultations per week
Inpatient (median, IQR) 3 [2, 4] 89 5 [4, 6] 31
Outpatient (median, IQR) 2 [1, 4] 89 2 [2, 3] 31
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swabs on 40 to 80% of occasions (sometimes or often).
Most (89.3%; 92/103) participants believe the MRSA
prevalence rate to be 20% or less at their institution, and
would therefore rarely empirically prescribe antibiotics to
treat methicillin resistant Staphylococcus aureus (MRSA).
In Scenario 1 (Table 1), 82 unique antimicrobial ther-
apy regimens were recorded by 106 participants (Fig. 1).
Oral antibiotics alone were used by 13.2% (14/106) of
participants, while oral antibiotics with < 4 days of intra-
venous antibiotics were used by a further 15.1% (16/
106). Outpatient parenteral antibiotics were used by 57.
5% (61/106) of participants. The median (IQR) duration
of overall antibiotic therapy was 26 (17–45) days. The
median duration of intravenous antibiotic therapy was
10 (3–17) days and oral antibiotic therapy without con-
current intravenous antibiotics was 14 (14–28) days. The
duration of antibiotic therapy did not differ between ID
physicians and Trainees (p = 0.93) or between clinicians in
Australia and New Zealand (p = 0.80). Figure 1 displays
the treatment regimens used for Scenario 1; 82.1% (87/
106) of participants used intravenous piperacillin-
tazobactam or ticarcillin-clavulanate as part of their treat-
ment; 91.5% (97/106) covered Pseudomonas aeruginosa at
the start of their regimen and 76.4% (81/106) of partici-
pants covered this pathogen during their entire regimen.
The preferred investigation for osteomyelitis in Scenario
1 was MRI (80%; 88/110), while CT scan was recom-
mended by 9.1% (10/110) and bone scan by 6.4% (7/110).
If methicillin sensitive Staphylococcus aureus (MSSA)
alone was isolated from deep intraoperative specimens,
86.5% (86/104) of participants indicated they would
change their treatment strategy.
In Scenario 2 (Table 1), 76 unique antimicrobial ther-
apy regimens were recorded by 101 participants (Fig. 2).
Oral antibiotics alone were used by 5.0% (5/101) and ≤
14 days of intravenous antibiotics were used by 20.8%
(21/101). Outpatient parenteral antibiotics were used by
85.1% (86/106) of participants. The median duration of
overall antibiotic therapy was 91 (63–107) days. The me-
dian duration of intravenous therapy was 31 (17–42)
days and oral therapy without concurrent intravenous
antibiotics was 60 (28–90) days. There was no significant
difference in duration of treatment between Physicians
and Trainees (p = 0.73) or Australian and New Zealand
clinicians (p = 0.21). Overall, 79.2% (80/101) gave intra-
venous flucloxacillin or cephazolin as part of their
Fig. 1 Type of antibiotics and duration chosen by respondents (n = 106) for Scenario 1. IV = intravenous; = PO per oral. † includes one each of
ceftazidime and flucloxacillin; ceftazidime; flucloxacillin and gentamicin. ‡ includes one each of clindamycin; flucloxacillin and trimethoprim-
sulfamethoxazole; trimethoprim-sulfamethoxazole and moxifloxacin; flucloxacillin
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treatment and only 13.9% (14/101) prescribed antibiotics
that would treat Gram-negative organisms during the
entire duration of antibiotic treatment (Fig. 2).
Discussion
This survey captured approximately one third of prac-
ticing ID clinicians in Australia and New Zealand and
demonstrates that on average a substantial proportion
(19.2%) of ID clinicians’ caseload in Australia and New
Zealand relates to the management of DFI. This is in
keeping with a 2012 snapshot of ID clinical practice in
the region [23] and reflects the increasing burden of dia-
betes and its associated complications [1–4, 24]. The
study also demonstrates the substantial heterogeneity
that exists in ID clinicians’ approach and management of
DFI. These findings highlight the need for Australian
and New Zealand ID Trainees to receive increased clin-
ical training in the management of DFI, be more in-
volved in MDT and to assist in clinical trial design and
implementation to guide development of regional evi-
dence based guidelines that will improve the manage-
ment of patients with DFI in Australasia.
Most participants managed patients with DFI as inpa-
tients in a public hospital setting. This may reflect a
higher rate of diabetes and diabetic complications in the
population that attends public hospitals, increased
multi-disciplinary expertise in foot-care in the public
sector, the caseload of ID consultations, or simply reflect
the experiences of the participants as a subgroup of total
ID practice. The majority had access to outpatient par-
enteral antimicrobial therapy (OPAT); an effective mode
of treatment that can contribute to significant healthcare
savings [25]. Apart from administering intravenous anti-
biotics, OPAT teams are also experienced in manage-
ment of complex chronic wounds and negative pressure
wound therapy. While the majority of participants were
familiar with OPAT to treat DFI, very few were involved
in telehealth consultations. Telehealth has been demon-
strated to improve diabetic foot outcomes as part of a
bundle of measures, when used by clinicians at remote
sites to seek advice and gain consensus opinion on diffi-
cult cases [10].
MDT management can play an important role in
improving patient outcomes as part of a multi-faceted
approach to DFI [10, 26–28]. Despite multiple
Fig. 2 Type of antibiotics and duration chosen by respondents (n = 106) for Scenario 2. IV = intravenous; = PO per oral
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recommendations for a uniform national model for such
a service [29], a uniform model is yet to be developed.
In this survey, respondents indicated MDT management
was available for respondents for 50% and 59% of inpa-
tients and outpatients, respectively. However, although
the characteristics of MDTs varied significantly, the ma-
jority included ID physicians.
Local guidelines for management of DFI exist in Austra-
lasia [22]; yet the heterogeneous nature of DFI may mean
that the relevant guideline may not be considered general-
isable to individual patients. When directly asked about
use of antibiotics for an acute infection of mild to moder-
ate severity the majority (76.7%) of participants described
using the oral antibiotics recommended in the guidelines
most (> 60%) of the time. However, in response to a clin-
ical scenario describing a patient with a five-week history
of a deep ulcer (categorised as an infection of moderate se-
verity), only 13.2% of respondents used oral therapy and a
further 15.1% used a course of intravenous antibiotics less
than 4 days followed by oral therapy. As such, 71.7% re-
spondents who used a more prolonged intravenous course
were not complying with the suggested Australian guide-
lines [22]. This result highlights the difficulties in deter-
mining appropriate management in DFI, in this case in
classifying the severity of the infection, in order to dis-
criminate treatment modalities or treatment durations
using current guidelines. It is also possible that clinicians
may be unaware of the guidelines, or sceptical of the value
of guidelines in view of their lack of evidence base. In the
other clinical scenario, the challenge in applying current
guidelines was also demonstrated, with participants choos-
ing a range of different treatment options which would be
consistent with both acute and chronic osteomyelitis.
The heterogeneity of the treatment regimens pre-
scribed by respondents likely reflects the lack of consen-
sus in management of DFI. This is most likely due to a
combination of:
i) a lack of high quality randomised controlled trial-
based evidence to inform guidelines;
ii) the heterogeneous nature of DFI that not only
restricts enrolment of uniform patients into clinical
trials but potentially prevents clinical trial results
from being generalisable;
iii) the multiple confounding factors that impact the
efficacy of antibiotics in the management of DFIs,
including difficulties in source control, poor supply
of nutrients and antibiotics due to micro- and
macrovascular factors and compliance with the
medical care bundle including orthotic use.
iv) the spectrum of DFI outcomes where some patients
will inevitably fail to heal. Such failure to heal risks
retrospectively being blamed upon early antibiotic
cessation or inadequate antimicrobial coverage, which
may pre-emptively influence a clinician’s judgement as
to the best antibiotic regimen and duration; and
v) a lack of awareness of the grading and management
of DFI according to published guidelines.
The heterogeneity in recommended management, such
as oral versus intravenous antibiotic administration, dem-
onstrates clinical equipoise, supporting the ethical argu-
ment for performance of randomised controlled trials
studying antimicrobial management of DFI.
Despite considerable heterogeneity in management
there were some areas of consistency: i) MRI was con-
sidered the preferred option to investigate potential
osteomyelitis; ii) the majority of clinicians in hospitals
with a perceived low or intermediate prevalence of
MRSA (< 20%) do not cover MRSA empirically and iii)
intravenous followed by oral flucloxacillin was the treat-
ment of choice for patients with MSSA osteomyelitis,
with only 13.9% treating for Gram-negative organisms
despite the ulcer having been present for 6 weeks.
Whether to treat organisms found on superficial swabs
remains a difficult decision, with respondents divided as
to whether they would cover organisms obtained from
superficial swabs. Sampling for microbiological speci-
mens should ideally be uniform with deep tissue samples
collected and processed in a standardised manner [30].
Our experience suggests this is uncommon and superfi-
cial swabs may be the only microbiological specimens
that an ID clinician has to base management decisions
upon. However, as demonstrated in Clinical Scenario 1,
when well-collected samples only cultured MSSA, the
majority of clinicians (86.5%) would adjust antibiotics
based upon this.
This study has limitations. There is a high likelihood
of a response bias, with clinicians that commonly see
such patients being more inclined to participate in this
survey. However, this is offset by a response rate of
nearly one third of all practicing ID clinicians, the pro-
portional uniformity of the caseload across different cat-
egories of respondents and the similarities to a previous
study that found 19% of ID consultations from the re-
gion were for people with diabetes [23]. As the majority
of the respondents in this study worked in the public
sector, our data may not be generalisable to physicians
practicing in private. Lastly, scenario-based assessment
of clinical management is limited by difficulties in repli-
cating the multiple variables that impact on a clinician’s
management decision, as well as the clinical response at dif-
ferent time points that may change an initial management
plan. However, the heterogeneity in treatment regimens in
this survey reflects real-world clinical experience and the
complexity of this patient group. These results could be
supported by additional cohort study data, that may pro-
vide further evidence of heterogeneity in clinical practice.
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Conclusions
This study found nearly one in every five consultations
provided by Australian and New Zealand ID Physicians
and Trainees were for patients with DFI, and that the
treatment recommended is heterogeneous. The study
highlights the need for outcome-directed randomised
clinical trials. Patients with DFI currently form an inte-
gral part of an ID Physician’s practice and because this is
likely to increase in the future, the ID community needs
to continue to recognise the importance of DFI as a sig-
nificant component of ID practice and training.
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